Maze looks to lead IPO queue with $113M Nas­daq de­but

Maze Ther­a­peu­tics is eye­ing a $113 mil­lion ini­tial pub­lic of­fer­ing a lit­tle un­der two months af­ter re­veal­ing a $115 mil­lion Se­ries D.

The clin­i­cal-stage biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER